FREMONT, Calif.--(BUSINESS WIRE)--Cordis Corporation today announced three-year clinical outcomes from the STROLL Trial at the Abstracts and Late Breaking Clinical Trials session at the 26th Annual International Symposium on Endovascular Therapy (ISET). Results from the trial showed that patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) treated with the S.M.A.R.T.® Vascular Stent System (S.M.A.R.T.® Stent) experienced sustained clinical and quality of life benefits out to three years, including improvements in physical, psychological and social function.
Help employers find you! Check out all the jobs and post your resume.
